Erratum: C11orf95-RELA fusions drive oncogenic NF-ΰ B signalling in ependymoma (Nature (2014) 506 (451-455 ) DOI:10.1038/nature13109);C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma

Nature

Volumn 506, Issue 7489, 2014, Pages 451-455

  Parker, Matthew ^a   Mohankumar, Kumarasamypet M ^a   Punchihewa, Chandanamali ^a   Weinlich, Ricardo ^a   Dalton, James D ^a   Li, Yongjin ^a   Lee, Ryan ^a   Tatevossian, Ruth G ^a   Phoenix, Timothy N ^a   Thiruvenkatam, Radhika ^a   White, Elsie ^a   Tang, Bo ^a   Orisme, Wilda ^a   Gupta, Kirti ^a   Rusch, Michael ^a   Chen, Xiang ^a   Li, Yuxin ^a   Nagahawhatte, Panduka ^a   Hedlund, Erin ^a   Finkelstein, David ^a   Wu, Gang ^a   Shurtleff, Sheila ^a   Easton, John ^a   Boggs, Kristy ^a   Yergeau, Donald ^a   Vadodaria, Bhavin ^a   Mulder, Heather L ^a   Becksford, Jared ^a   Gupta, Pankaj ^a   Huether, Robert ^a   Ma, Jing ^a   Song, Guangchun ^a   Gajjar, Amar ^a   Merchant, Thomas ^a   Boop, Frederick ^a   Smith, Amy A ^b   Ding, Li ^a,c   Lu, Charles ^a,c   Ochoa, Kerri ^a,c   Zhao, David ^a   Fulton, Robert S ^a,c   Fulton, Lucinda L ^a,c   Mardis, Elaine R ^a,c,d   Wilson, Richard K ^a,c,d   Downing, James R ^a   Green, Douglas R ^a   Zhang, Jinghui ^a   Ellison, David W ^a   Gilbertson, Richard J ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b M D ANDERSON CANCER CENTER ORLANDO   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Washington University in St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN C11ORF95; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

CANCER; CHROMOSOME; GENE; MEMBRANE; MUTATION; PROTEIN; RODENT; SIGNALING; TUMOR;

ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL MIGRATION; CHROMOSOME 11Q; CONTROLLED STUDY; EPENDYMOMA; FEMALE; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

MUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BASE SEQUENCE; BRAIN NEOPLASMS; CELL LINE; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 11; EPENDYMOMA; FEMALE; HUMANS; MICE; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; NEURAL STEM CELLS; NF-KAPPA B; ONCOGENE PROTEINS, FUSION; PHOSPHOPROTEINS; PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TRANSLOCATION, GENETIC;

EID: 84896721467     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13299     Document Type: Erratum

References (28)

1. Kleihues, P. et al. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61, 215-225; discussion 226-219 (2002).
2. Merchant, T. E. et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol. 10, 258-266 (2009).
3. Modena, P. et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J. Clin. Oncol. 24, 5223-5233 (2006).
4. Taylor, M. D. et al. Radial glia cells are candidate stemcells of ependymoma. Cancer Cell 8, 323-335 (2005).
5. Puget, S. et al. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J. Clin. Oncol. 27, 1884-1892 (2009).
6. Johnson, R. A. et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature 466, 632-636 (2010).
7. Witt, H. et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20, 143-157 (2011).
8. Atkinson, J. M. et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20, 384-399 (2011).
9. Wang, J. et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nature Methods 8, 652-654 (2011).
10. Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27-40 (2011).
11. Nolan, G. P., Ghosh, S., Liou, H. C., Tempst, P. & Baltimore, D. DNA binding and IkB inhibition of the cloned p65 subunit of NF-kB, a rel-related polypeptide. Cell 64, 961-969 (1991).
12. Hansen, S. K., Baeuerle, P. A. & Blasi, F. Purification, reconstitution, and I kappa B association of the c-Rel-p65 (RelA) complex, a strong activator of transcription. Mol. Cell. Biol. 14, 2593-2603 (1994).
13. DiDonato, J. A., Mercurio, F. & Karin, M. NF-kB and the link between inflammation and cancer. Immunol. Rev. 246, 379-400 (2012).
14. Perkins, N. D. The diverse and complex roles of NF-kB subunits in cancer. Nature Rev. Cancer 12, 121-132 (2012).
15. Baud, V. & Karin, M. Is NF-kB a good target for cancer therapy? Hopes and pitfalls. Nature Rev. Drug Discov. 8, 33-40 (2009).
16. Chaturvedi, M. M., Sung, B., Yadav, V. R., Kannappan, R. & Aggarwal, B. B. NF-kB addiction and its role in cancer: 'one size does not fit all'. Oncogene 30, 1615-1630 (2011).
17. Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G. & Baldwin, A. S. NF-kB controls cell growth and differentiation through transcriptional regulation of cyclin d1. Mol. Cell. Biol. 19, 5785-5799 (1999).
18. Hinz, M. et al. NF-kB function in growth control: regulation of cyclin d1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19, 2690-2698 (1999).
19. Kiefel, H., Pfeifer, M., Bondong, S., Hazin, J. & Altevogt, P. Linking L1CAM-mediated signaling to NF-kB activation. Trends Mol. Med. 17, 178-187 (2011).
20. Kiefel, H. et al. EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-kB activation. Carcinogenesis 33, 1919-1929 (2012).
21. Courtois, G. & Gilmore, T. D. Mutations in the NF-kB signaling pathway: implications for human disease. Oncogene 25, 6831-6843 (2006).
22. Godfraind, C. et al. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol. 124, 247-257 (2012).
23. Chen, L.-F. & Greene, W. C. Shaping the nuclear action of NF-kB. Nature Rev. Mol. Cell Biol. 5, 392-401 (2004).
24. Zhong, H., Voll, R. E. & Ghosh, S. Phosphorylation of NF-kB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Molecular Cell 1, 661-671 (1998).
25. Okazaki, T. et al. Phosphorylation of serine 276 is essential for p65 NF-kB subunitdependent cellular responses. Biochem. Biophys. Res. Commun. 300, 807-812 (2003).
26. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157-163 (2012).
27. Robinson, G. et al. Novel mutations target distinct subgroups ofmedulloblastoma. Nature 488, 43-48 (2012).
28. Korbel, J. O. & Campbell, P. J. Criteria for inference of chromothripsis in cancer genomes. Cell 152, 1226-1236 (2013).